Overview
Life science tools firm's Q4 revenue decreased 1% but beat analyst expectations
Adjusted EPS for Q4 met analyst expectations
Company is implementing Revival program, including VWR brand relaunch and e-commerce upgrades
Outlook
Company is focusing on top-line growth and strategic investments in 2026
Avantor aims to create sustainable shareholder value through strategic initiatives
Revival program includes relaunch of VWR brand and e-commerce upgrades
Result Drivers
REVIVAL PROGRAM - Avantor is executing a Revival program to improve agility and customer focus, including VWR brand relaunch and e-commerce upgrades
FOREIGN CURRENCY IMPACT - Foreign currency translation positively impacted sales, offsetting some of the organic decline
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $1.66 bln | $1.64 bln (16 Analysts) |
Q4 Adjusted EPS | Meet | $0.22 | $0.22 (18 Analysts) |
Q4 Net Income | $52.40 mln | ||
Q4 Gross Profit | $523.90 mln | ||
Q4 Operating Income | $126.40 mln | ||
Q4 Pretax Profit | $80.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 15 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Avantor Inc is $12.05, about 8% above its February 10 closing price of $11.16
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 13 three months ago
Press Release: ID:nPn1Mz9V5a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments